Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
Posted inCardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.
Live Birth Rates Independent of Sex-Steroid Levels in Dydrogesterone-Based Programmed-Ovulatory FET: A Shift in Luteal Support Monitoring?
Posted innews OB/GYN & Women's Health

Live Birth Rates Independent of Sex-Steroid Levels in Dydrogesterone-Based Programmed-Ovulatory FET: A Shift in Luteal Support Monitoring?

A multicentric study demonstrates that sex-steroid levels on the day of embryo transfer do not predict live birth rates in a novel programmed-ovulatory FET protocol using dydrogesterone, suggesting that routine hormonal monitoring may be unnecessary when corpus luteum function is preserved.
Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience
Posted inNeurology news Pathology & Lab Medicine

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.
Comparative Efficacy, Safety, and Complications of Subcutaneous Versus Transvenous Implantable Cardioverter-Defibrillators: Insights from the PRAETORIAN and ATLAS Trials and Meta-Analyses
Posted inCardiology Clinical Updates news

Comparative Efficacy, Safety, and Complications of Subcutaneous Versus Transvenous Implantable Cardioverter-Defibrillators: Insights from the PRAETORIAN and ATLAS Trials and Meta-Analyses

This review synthesizes randomized trial data comparing subcutaneous and transvenous ICDs, highlighting differences in inappropriate shocks, device-related complications, and shock efficacy, underscoring clinical considerations for ICD selection.
High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD
Posted inCardiology Internal Medicine news

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI above 35 kg/m2, emphasizing a targeted therapeutic advantage for this high-risk population.